semaglutide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42251860
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
- 저자
- Vanita R Aroda, Raffaella Buzzetti, Stine-Mathilde Dalskov, Akshay B Jain, Jonas Hughes Larsen, Chantal Mathieu
- 저널
- The lancet. Diabetes & endocrinology
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1016/S2213-8587(26)00126-9
문헌 요약
Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. REIMAGINE 1 was a randomised, double-blind, p…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.